Full Text Full Text (PDF) CME: Take the course for this article: AJP CME Course for March 2007: Effects of Antipsychotic Medications on Psyc... Data Supplement Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Swartz, M. S. Search for Related Content PubMed Citation Articles by Swartz, M. S. Schizophrenia Spectrum Disorders Atypical Neuroleptics Related Article

Effects of Antipsychotic Medications on Psychosocial Functioning in Patients With Chronic Schizophrenia: Findings From the NIMH CATIE Study

OBJECTIVE: This study examined the relative effects of the second-generation antipsychotic drugs and an older representative agent on psychosocial functioning in patients with chronic schizophrenia. METHOD: Consenting patients were enrolled in the NIMH Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project. In phase 1, patients were randomly assigned to receive olanzapine, perphenazine, quetiapine, risperidone, or ziprasidone for up to 18 months. Clozapine was included for patients who chose this pathway after discontinuing phase 1 due to inefficacy; all other patients received another second-generation antipsychotic. Psychosocial functioning was assessed using the Quality of Life Scale. RESULTS: Psychosocial functioning modestly improved for the one-third of phase 1 patients who reached the primary Quality of Life Scale analysis endpoint of 12 months (average effect size 0.19 SD units). Although for several of the drugs individually there were significant changes from baseline, overall there were no significant differences between the different agents. Results were similar at 6 and 18 months. There were no significant differences among the treatment groups in the amount of change in the Quality of Life Scale total score or subscale scores at 6, 12, or 18 months. Patients treated with clozapine in the efficacy pathway made comparable gains. Early treatment discontinuations, especially among patients most impaired at baseline, limited the ability to achieve more substantial functional gains. CONCLUSIONS: All antipsychotic treatment groups in all phases made modest improvements in psychosocial functioning. There were no differences among them after 6, 12, or 18 months. More substantial improvements would likely require more intensive adjunctive psychosocial rehabilitation interventions.

Related Article:

In This Issue
Am J Psychiatry 2007 164: 62. [Full Text] [PDF]

This article has been cited by other articles:

				M. S. Swartz, T. S. Stroup, J. P. McEvoy, S. M. Davis, R. A. Rosenheck, R. S. E. Keefe, J. K. Hsiao, and J. A. Lieberman What CATIE Found: Results From the Schizophrenia Trial Psychiatr Serv, May 1, 2008; 59(5): 500 - 506. [Abstract] [Full Text] [PDF]

				R. A. Rosenheck, D. L. Leslie, and J. A. Doshi Second-Generation Antipsychotics: Cost-Effectiveness, Policy Options, and Political Decision Making Psychiatr Serv, May 1, 2008; 59(5): 515 - 520. [Abstract] [Full Text] [PDF]

				N. H. Covell, M. T. Finnerty, and S. M. Essock Implications of CATIE for Mental Health Services Researchers Psychiatr Serv, May 1, 2008; 59(5): 526 - 529. [Abstract] [Full Text] [PDF]

				J. J. Parks, A. Q. Radke, and R. Tandon Impact of the CATIE Findings on State Mental Health Policy Psychiatr Serv, May 1, 2008; 59(5): 534 - 536. [Abstract] [Full Text] [PDF]

				J. Parks, A. Radke, G. Parker, M.-E. Foti, R. Eilers, M. Diamond, D. Svendsen, and R. Tandon Principles of Antipsychotic Prescribing for Policy Makers, Circa 2008. Translating Knowledge to Promote Individualized Treatment Schizophr Bull, April 2, 2008; (2008) sbn019v1. [Abstract] [Full Text] [PDF]

				S. M. Eack and M. S. Keshavan Foresight in Schizophrenia: A Potentially Unique and Relevant Factor to Functional Disability Psychiatr Serv, March 1, 2008; 59(3): 256 - 260. [Abstract] [Full Text] [PDF]

				R.A. Rosenheck, D.L. Leslie, S. Busch, E. S. Rofman, and M. Sernyak Rethinking Antipsychotic Formulary Policy Schizophr Bull, March 1, 2008; 34(2): 375 - 380. [Abstract] [Full Text] [PDF]

				T. S. Stroup and J. R. Geddes Randomized Controlled Trials for Schizophrenia: Study Designs Targeted to Distinct Goals Schizophr Bull, March 1, 2008; 34(2): 266 - 274. [Abstract] [Full Text] [PDF]

				Bibliography Schizophrenia Focus, January 1, 2008; 6(2): 197 - 199. [Full Text] [PDF]

				N. Bergemann, P. Parzer, S. Jaggy, B. Auler, C. Mundt, and S. Maier-Braunleder Estrogen and Comprehension of Metaphoric Speech in Women Suffering From Schizophrenia: Results of a Double-Blind, Placebo-Controlled Trial Schizophr Bull, December 21, 2007; (2007) sbm138v1. [Abstract] [Full Text] [PDF]

				O. Bembom and M. J. van der Laan Statistical Methods for Analyzing Sequentially Randomized Trials J Natl Cancer Inst, November 7, 2007; 99(21): 1577 - 1582. [Abstract] [Full Text] [PDF]

				R. A. Rosenheck Evaluating the cost-effectiveness of reduced tardive dyskinesia with second-generation antipsychotics The British Journal of Psychiatry, September 1, 2007; 191(3): 238 - 245. [Abstract] [Full Text] [PDF]

				S. Hamer and P. M. Haddad Adverse effects of antipsychotics as outcome measures The British Journal of Psychiatry, August 1, 2007; 191(50): s64 - s70. [Abstract] [Full Text] [PDF]

Get information about faster international access.

Privacy Policy

Copyright © 2007 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us